Vancouver, British Columbia--(Newsfile Corp. - April 7, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company primarily focused on the development of novel vaccines and drug delivery technologies, is pleased to announced that the United States Patent and Trademark Office (USPTO) has granted patent number US 11,291,717 ('717) covering its breakthrough vaccine platform technology for the treatment/prevention of a wide range of cancers and infectious diseases, including SARS-CoV-2. This platform utilizes components of Defence's proprietary Accum™ technology attached to various tumor, viral, or bacterial antigens to enhance both humoral and cellular immunity, providing remarkable protection in challenge studies. The '717 patent provides broad protection for Defence's extremely versatile vaccine platform that can be incorporated into virtually any cell-based or protein subunit vaccine to enhance immunogenicity.
Defence's '717 patent was allowed by the USPTO within an expedient three months without any substantive amendments, which is a strong testament to the novelty and inventiveness of the pioneering technology, as well as to the robust data supporting the utility and versatility of the vaccine platform. Included in the '717 patent are claims directed to immunogenic compositions of matter comprising Defence's first and subsequent generation Accum™ technologies, as well as methods directed to their production and use in vaccination and/or immunotherapy.
"This US patent is not only another important milestone in protecting the commercial potential of Accum™, but along with new patent families currently in the pipeline, demonstrates Defence's strong overall commitment to protecting the innovation and commercial potential of the entire product portfolio as well as to becoming a leader in vaccine development," said Sebastien Plouffe, Chief Executive Officer of Defence Therapeutics Inc.
About Defence:
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the AccumTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements." All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119497
